Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure

World Journal of Gastroenterology

Volumn 12, Issue 41, 2006, Pages 6678-6682

  Kotoh, Kazuhiro ^a   Enjoji, Munechika ^a   Nakamuta, Makoto ^a   Yoshimoto, Tsuyoshi ^a   Kohjima, Motoyuki ^a   Morizono, Shusuke ^a   Yamashita, Shinsaku ^a   Horikawa, Yuki ^a   Yoshimitsu, Kengo ^a   Tajima, Tsuyoshi ^a   Asayama, Yoshiki ^a   Ishigami, Kousei ^a   Hirakawa, Masakazu ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Acute hepatic failure; Fulminant liver failure; Macrophage; Methlyprednisolone; Multiple logistic analysis

Indexed keywords

ALBUMIN; METHYLPREDNISOLONE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HEPATIC ARTERY; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HUMAN; LIVER FAILURE; LIVER SUPPORT; LIVER TRANSPLANTATION; MACROPHAGE ACTIVATION; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PROGNOSIS; PROTHROMBIN TIME; THROMBOCYTE COUNT;

EID: 33751298473     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i41.6678     Document Type: Article

References (22)

1. Bernuau J, Benhamou J. Fulminant and subfulminant liver failure. In: Bircher J, Benhamou J, McIntyre N, Rizzetto M, Rodés J, eds. Oxford textbook of clinical hepatology. Oxford: OXFORD UNIVERSITY press, 1999: 1341-1372
2. Ascher NL, Lake JR, Emond JC, Roberts JP. Liver transplantation for fulminant hepatic failure. Arch Surg 1993; 128: 677-682
3. Takikawa Y, Endo R, Suzuki K, Fujiwara K, Omata M. Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci 2006; 51: 359-364
4. Miyake Y, Sakaguchi K, Iwasaki Y, Ikeda H, Makino Y, Kobashi H, Araki Y, Ando M, Kita K, Shiratori Y. New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure. Transplantation 2005; 80: 930-936
5. Dhiman RK, Seth AK, Jain S, Chawla YK, Dilawari JB. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig Dis Sci 1998; 43: 1311-1316
6. Elinav E, Ben-Dov I, Hai-Am E, Ackerman Z, Ofran Y. The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy. J Hepatol 2005; 42: 82-86
7. Dabos KJ, Newsome PN, Parkinson JA, Mohammed HH, Sadler IH, Plevris JN, Hayes PC. Biochemical prognostic markers of outcome in non-paracetamol-induced fulminant hepatic failure. Transplantation 2004; 77: 200-205
8. Davenport A, Will EJ, Davison AM. Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure. Kidney Int Suppl 1993; 41: S245-S251
9. Sato S, Suzuki K, Takikawa Y, Endo R, Omata M. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res 2004; 30: 155-161
10. Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian S, Wright H, Nour B, Sebastian A. The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher 2006; 21: 96-99
11. Sekido H, Matsuo K, Takeda K, Ueda M, Morioka D, Kubota T, Tanaka K, Endo I, Togo S, Shimada H. Usefulness of artificial liver support for pretransplant patients with fulminant hepatic failure. Transplant Proc 2004; 36: 2355-2356
12. Matsui A, Mochida S, Ohno A, Nagoshi S, Hirose T, Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol Res 2004; 29: 202-206
13. Hiraoka A, Horiike N, Akbar SM, Michitaka K, Matsuyama T, Onji M. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure. J Gastroenterol 2005; 40: 52-56
14. Mita A, Hashikura Y, Tagawa Y, Nakayama J, Kawakubo M, Miyagawa S. Expression of Fas ligand by hepatic macrophages in patients with fulminant hepatic failure. Am J Gastroenterol 2005; 100: 2551-2559
15. Iwaki T, Sugimura M, Nishihira J, Matsuura T, Kobayashi T, Kanayama N. Recombinant adenovirus vector bearing antisense macrophage migration inhibitory factor cDNA prevents acute lipopolysaccharide-induced liver failure in mice. Lab Invest 2003; 83: 561-570
16. Balow JE, Rosenthal AS. Glucocorticoid suppression of macrophage migration inhibitory factor. J Exp Med 1973; 137: 1031-1041
17. Grasso RJ, Klein TW, Benjamin WR. Inhibition of yeast phagocytosis and cell spreading by glucocorticoids in cultures of resident murine peritoneal macrophages. J Immunopharmacol 1981; 3: 171-192
18. Ware AJ, Cuthbert JA, Shorey J, Gurian LE, Eigenbrodt EH, Combes B. A prospective trial of steroid therapy in severe viral hepatitis. The prognostic significance of bridging necrosis. Gastroenterology 1981; 80: 219-224
19. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 75-79
20. Rakela J, Mosley JW, Edwards VM, Govindarajan S, Alpert E. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci 1991; 36: 1223-1228
21. Misra NC, Jaiswal MS, Singh RV, Das B. Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. Cancer 1977; 39: 1425-1429
22. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K, Tanimoto M. Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 2003; 23: 1891-1897